2026-04-28T21:35:20Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/232562024-11-29T03:58:02Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967col_20.500.12105_16973

00925njm 22002777a 4500 dc Hernandez Rodriguez, Miguel Angel author Sempere-Verdú, Ermengol author Vicens-Caldentey, Caterina author González-Rubio, Francisca author Miguel-García, Félix author Palop-Larrea, Vicente author Orueta-Sánchez, Ramón author Esteban-Jimenez, Oscar author Sempere-Manuel, Mara author Arroyo-Aniés, María Pilar author Fernández-San José, Buenaventura author de Juan-Roldán, José Ignacio author Ioakeim-Skoufa, Ignatios author 2021-04-29 We aimed to identify and compare medication profiles in populations with polypharmacy between 2005 and 2015. We conducted a cross-sectional study using information from the Computerized Database for Pharmacoepidemiologic Studies in Primary Care (BIFAP, Spain). We estimated the prevalence of therapeutic subgroups in all individuals 15 years of age and older with polypharmacy (≥5 drugs during ≥6 months) using the Anatomical Therapeutic Chemical classification system level 4, by sex and age group, for both calendar years. The most prescribed drugs were proton-pump inhibitors (PPIs), statins, antiplatelet agents, benzodiazepine derivatives, and angiotensin-converting enzyme inhibitors. The greatest increases between 2005 and 2015 were observed in PPIs, statins, other antidepressants, and β-blockers, while the prevalence of antiepileptics was almost tripled. We observed increases in psychotropic drugs in women and cardiovascular medications in men. By patient´s age groups, there were notable increases in antipsychotics, antidepressants, and antiepileptics (15-44 years); antidepressants, PPIs, and selective β-blockers (45-64 years); selective β-blockers, biguanides, PPIs, and statins (65-79 years); and in statins, selective β-blockers, and PPIs (80 years and older). Our results revealed important increases in the use of specific therapeutic subgroups, like PPIs, statins, and psychotropic drugs, highlighting opportunities to design and implement strategies to analyze such prescriptions' appropriateness. Hernández-Rodríguez MA, Sempere-Verdú E, Vicens-Caldentey C, González-Rubio F, Miguel-García F, Palop-Larrea V, et al. Drug prescription profiles in patients with polypharmacy in spain: A large-scale pharmacoepidemiologic study using real-world data. Int J Environ Res Public Health. 2021 May 1;18(9). https://hdl.handle.net/20.500.13003/18709 https://hdl.handle.net/20.500.12105/23256 33946914 10.3390/ijerph18094754 1660-4601 International journal of environmental research and public health 2-s2.0-85105431923 650252400001 L2007056720 Computerized medical records systems Drug utilization Electronic prescribing Pharmacoepidemiology Polypharmacy Real-world data Spain Drug Prescription Profiles in Patients with Polypharmacy in Spain: A Large-Scale Pharmacoepidemiologic Study Using Real-World Data